Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Show more
Location: Tuborg Boulevard 12, Hellerup, 2900, Denmark | Website: https://ascendispharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
10.41B
52 Wk Range
$111.09 - $183.00
Previous Close
$172.00
Open
$170.19
Volume
270,610
Day Range
$170.19 - $174.34
Enterprise Value
10.75B
Cash
517.9M
Avg Qtr Burn
-54.73M
Insider Ownership
0.78%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YORVIPATH® (palopegteriparatide, developed as TransCon PTH) Details Adult hypoparathyroidism | Approved Quarterly sales | |
SKYTROFA (TransCon hGH) (lonapegsomatropin) Details Pediatric growth hormone deficiency | Approved Quarterly sales | |
TransCon CNP Details Achondroplasia | PDUFA Approval decision | |
TransCon hGH Details Adult growth hormone deficiency | PDUFA Approval decision | |
TransCon IL-2 B/y + TLR7/8 Details Solid tumor/s, Cancer | Phase 2 Data readout | |
TransCon hGH/TransCon CNP combination Details Achondroplasia | Phase 2 Data readout | |
TransCon hGH Details Turner syndrome | Phase 2 Data readout | |
TransCon TLR7/8 Agonist +/- pembrolizumab Details Solid tumor/s, Cancer | Phase 2 Data readout | |
TransCon IL-2 B/y Details Cancer, Solid tumor/s | Phase 2 Data readout | |
TransCon CNP Details Achondroplasia | Phase 2 Update |